poisar

Stocks · News reference

REGENXBIO Completes Enrollment in Pivotal Sura-Vec Trials and Reports Q3 2026 Financials

Fiscal.ai

REGENXBIO has finished enrolling over 1,300 patients in its pivotal ATMOSPHERE and ASCENT clinical trials for sura-vec, with data expected in Q4 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    Regenxbio Q3 2026 Earnings Call Transcript

    Regenxbio (NASDAQ:RGNX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

  2. SEC EDGARSEC EDGAR

    8-K filing — REGENXBIO Inc. (RGNX)

    Filed: 2026-11-05 AccNo: 0001193125-26-448559 Size: 529 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits